1. Ibrutinib
   Giuseppe Tridente, 2017, Adverse Events and Oncotargeted Kinase Inhibitors CrossRef
2. Biomarkers and novel therapeutic approaches for diffuse large B-cell lymphoma in the era of precision medicine
   Niraj Lodhi et al, 2020, Oncotarget CrossRef
3. Process Development and Large-Scale Synthesis of BTK Inhibitor BIIB068
   Chaomin Li et al, 2020, Organic Process Research & Development CrossRef
4. Down-regulation of cylindromatosis protein phosphorylation by BTK inhibitor promotes apoptosis of non-GCB-diffuse large B-cell lymphoma
   Xin Xu et al, 2021, Cancer Cell International CrossRef
5. Discovery of (R)-5-(benzo[d][1,3]dioxol-5-yl)-7-((1-(vinylsulfonyl)pyrrolidin-2-yl)methyl)-7H-pyrrolo[2,3-d]pyrimidin-4-amine (B6) as a potent Bmx inhibitor for the treatment of NSCLC
   Linhong He et al, 2017, Bioorganic & Medicinal Chemistry Letters CrossRef
6. Structural and biophysical insights into the mode of covalent binding of rationally designed potent BMX inhibitors
   João D. Seixas et al, 2020, RSC Chemical Biology CrossRef
7. Forced Degradation Study of Zanubrutinib: An LC–PDA and LC–MS Approach
   Gowri Gollu et al, 2022, Journal of Chromatographic Science CrossRef
8. Therapeutic inhibition of USP7-PTEN network in chronic lymphocytic leukemia: a strategy to overcome TP53 mutated/deleted clones
   Giovanna Carrà et al, 2017, Oncotarget CrossRef
9. Evidence for interaction of the NLRP3 inflammasome and Bruton’s tyrosine kinase in tumor-associated macrophages: implications for myeloid cell production of interleukin-1beta
   Brooke Benner et al, 2019, OncoImmunology CrossRef
10. ZYBT1, a potent, irreversible Bruton’s Tyrosine Kinase (BTK) inhibitor that inhibits the C481S BTK with profound efficacy against arthritis and cancer
    Krishnarup Ghoshdastidar et al, 2020, Pharmacology Research & Perspectives CrossRef